Colorado Institute for Drug, Device and Diagnostic Development Sets August 5th as Submission Date for New Project Consideration
The Colorado Institute for Drug, Device and Diagnostic Development (CID4) is seeking its fifth project and a review date of Friday, August 5th has been selected as the cut-off for submitting material to CID4.com for consideration.
Aurora, CO, July 27, 2011 --(PR.com)-- The Colorado Institute for Drug, Device and Diagnostic Development (CID4), a 501(c)(3) not-for-profit entity focused on advancing the Colorado life science ecosystem through company creation and job growth, is seeking its fifth project. A review date of Friday, August 5th has been selected as the cut-off for submitting material to CID4.com for consideration.
CID4 recently launched a new website where business plans of all shapes and sizes are submitted online on a rolling basis. The new CID4 Innovation Database is proving to be a powerful tool, enabling industry partners and investors from all over world to reach into the technology-rich Colorado life science ecosystem. Providing an efficient, single point of entry, the database has been warmly received by both commercial partners and institutional investors and is being validated as an effective tool for catalyzing significant opportunities for Colorado entrepreneurs. Companies or technology business plans that had been uploaded to the CID4 Innovation Database were presented at the intense partnering and investor conferences C21 BioVentures in Napa, CA in May and BIO 2011 in Washington, D.C. in June.
Those companies and technologies who submit their content by the August 5th cut-off will be considered for review by management and the Technical and Business Advisory Committee (TBAC). For more details about the project selection process visit CID4.com. Rolling submissions received following the August 5th cut-off will be considered in the next project evaluation session, date announcement forthcoming.
“We look forward to this next evaluation cycle and are excited to bring new innovations to our TBAC and the Board,” said Kevin M. Smith, President and Chief Executive Officer of CID4. “Our first four projects have achieved important milestones in their drive to reach the market. The management and financial resources deployed by CID4 have had a material and measurable impact on their successes to date and we look forward to doing more.”
CID4 has committed $1.25 million to four projects, which have created 22 direct jobs and raised an additional $1.3 million of investment capital. CID4 is delivering on its mission of Economic Development through Innovation Advancement.
About the Colorado Institute for Drug, Device and Diagnostic Development
Founded in 2009, the Colorado Institute for Drug, Device and Diagnostic Development (CID4) is a 501(c)(3) not-for-profit charitable organization whose mission is to advance the Colorado bioscience ecosystem through company creation and job growth. Active business management and capital work in tandem to help bridge the gap between discovery and product development. CID4 works to identify, fund and actively manage emerging life science technologies. This aim is achieved via an ongoing technology solicitation process augmented by additional deal flow sourcing through networked relationships. Active due diligence is provided by CID4 management in consultation with members of the CID4 Technical and Business Advisory Committee. For more information visit http://CID4.com.
Contact:
Kevin M. Smith, President & CEO, CID4, kevin.smith@cid4.com, (720) 859-4043
###
CID4 recently launched a new website where business plans of all shapes and sizes are submitted online on a rolling basis. The new CID4 Innovation Database is proving to be a powerful tool, enabling industry partners and investors from all over world to reach into the technology-rich Colorado life science ecosystem. Providing an efficient, single point of entry, the database has been warmly received by both commercial partners and institutional investors and is being validated as an effective tool for catalyzing significant opportunities for Colorado entrepreneurs. Companies or technology business plans that had been uploaded to the CID4 Innovation Database were presented at the intense partnering and investor conferences C21 BioVentures in Napa, CA in May and BIO 2011 in Washington, D.C. in June.
Those companies and technologies who submit their content by the August 5th cut-off will be considered for review by management and the Technical and Business Advisory Committee (TBAC). For more details about the project selection process visit CID4.com. Rolling submissions received following the August 5th cut-off will be considered in the next project evaluation session, date announcement forthcoming.
“We look forward to this next evaluation cycle and are excited to bring new innovations to our TBAC and the Board,” said Kevin M. Smith, President and Chief Executive Officer of CID4. “Our first four projects have achieved important milestones in their drive to reach the market. The management and financial resources deployed by CID4 have had a material and measurable impact on their successes to date and we look forward to doing more.”
CID4 has committed $1.25 million to four projects, which have created 22 direct jobs and raised an additional $1.3 million of investment capital. CID4 is delivering on its mission of Economic Development through Innovation Advancement.
About the Colorado Institute for Drug, Device and Diagnostic Development
Founded in 2009, the Colorado Institute for Drug, Device and Diagnostic Development (CID4) is a 501(c)(3) not-for-profit charitable organization whose mission is to advance the Colorado bioscience ecosystem through company creation and job growth. Active business management and capital work in tandem to help bridge the gap between discovery and product development. CID4 works to identify, fund and actively manage emerging life science technologies. This aim is achieved via an ongoing technology solicitation process augmented by additional deal flow sourcing through networked relationships. Active due diligence is provided by CID4 management in consultation with members of the CID4 Technical and Business Advisory Committee. For more information visit http://CID4.com.
Contact:
Kevin M. Smith, President & CEO, CID4, kevin.smith@cid4.com, (720) 859-4043
###
Contact
Colorado Institute for Drug, Device and Diagnostic Development
Maggie Holben
303-984-9801
http://cid4.com
Maggie Holben
303-984-9801
http://cid4.com
Contact
Categories